Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 17170-006001

Application No. 10/077,596

Information Disclosure Statement by Applicant (Use several sheets if necessary)

Applicant Alan D. Snow et al.

Filing Date

Group Art Unit 1617 February 15, 2002

An English language abstract provided.

**=Already provided

		-		U.S. Pate	nt Documents			
	miner itial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
5	ZΥ	A	2002/0111309	08/15/02	Castillo et al.	514	12	08/22/01
	/	В	2002/0168753	11/14/02	Castillo et al.	435	226	11/30/01
		С	2002/0197692	12/26/02	Castillo et al.	435	184	11/02/01
		D	2003/0013648	01/16/03	Castillo et al.	514	12	09/24/01
		E	2003/0017998	01/23/03	Snow et al.	514	27	02/15/02
**		F	4,844,901	07/04/89	Keplinger et al.	424	195.1	05/16/88
**		G	4,940,725	07/10/90	Keplinger et al.	514	411	04/03/89
**		н	5,166,139	11/24/92	Bombardelli et al.	514	26	01/18/91
**	-	ı	5,302,611	04/12/94	Keplinger et al.	514	411	09/30/92
		J	5,643,562	07/01/97	Kisilevsky et al.	424	78.31	03/15/95
		К	5,767,126	06/16/98	Marchbanks	514	297	10/18/94
		L	5,681,569	10/28/97	Kuznicki et al.	424	195	11/06/95
		М	5,869,469	02/09/99	Szarek	514	120	08/18/97
•		N	5,958,883	09/28/99	Snow	514	16	06/05/95
		0	5,972,956	10/26/99	Hays et al.	514	297	04/29/98
		Р	5,981,168	11/09/99	Reiner	435	4	05/15/98
		Q	6,037,327	03/14/00	Castillo et al.	514	23	08/28/98
**	•	R	6,039,949	03/21/00	Pero	424	195.1,	02/27/97
		S	6,165,912	12/26/00	McConnell et al.	438	758	09/14/99
		Т	6,207,842	03/27/01	Romanczyk et al.	549	399	10/09/97
		U	6,264,994	07/24/01	Castillo et al.	424	725	12/08/98
\neg		V	6,297,281	10/02/01	de Lassauniere et al.	514	589	03/02/99
		w	6,340,783	01/22/02	Snow	800	12	10/03/96
**		х	6,346,280.	02/12/02	Castillo et al	424	725	11/24/98
		Y	6,432,636	08/13/02	Maresh et al.	435	6	08/26/97
		Z	6,563,016	05/13/03	Snow et al.	800	12	03/27/00
4	a y	AA	6,607,758	08/19/03	Castillo et al.	424	769	08/24/01

Examiner	Signature
----------	-----------

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Tracomark Office	17170-006001	Application No. 10/077,596
		Applicant KAlan D. Snow et al.	
(Use several s	heets if necessary) NAR 3 0	Filing Date February 15, 2002	Group Art Unit 1617
X+= An English language at	ostract provided.	**=Already provided	

X+= An English language abstract provided.

Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
320	AB	0 659 418 A1	06/28/95	EP				L
	AC	1 014 996 B1	05/28/03	EP				
	AD	10-245342	09/14/98	JP			X+]
	AE	1-151514	06/14/89	JP				X+
	AF	00/12102	03/09/00	РСТ				
	AG	00/57707	10/05/00	PCT				
	AH	01/49281	07/12/01	PCT				
	AI	01/49307	07/12/01	PCT				
	AJ	02/062422	08/15/02	PCT				
	AK	02/076381	10/03/02	PCT				<u> </u>
	AL	97/46664	12/11/97	PCT				
	AM	98/08381	03/05/98	PCT				
	AN	98/09653	03/12/98	PCT				<u> </u>
	AO	98/34646	08/13/98	PCT				
	AP	98/39653	09/11/98	PCT				
	AQ	98/51302	11/19/98	PCT				
541	AR	99/09999	03/04/99	PCT				

	Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner	Desig.							
Initial	ID	<u>Document</u>						
597	AS	"Progress Report on Alzheimers Disease," The National Institute on Aging, National Institutes of Health, 1997.						
	АТ	Arai et al, "Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/α-synuclein," Neurosc. Lett. 259:83-86 (1999)						
**	AU	Barner et al. "Donepezil Use in Alzheimer Disease," The Annals of Pharmacotherupy, 32:70-77, (1998)						
590	AV	Baumann et al, "A simple isolation method for the major catechins in green tea using high-speed countercurrent chromatography," J. Natural Prod. 64:353-355, (2001)						

Examiner Signature	Date Considered 6/9/64
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	ot in conformance and not considered. Include copy of this form with
TOX COMMENTACION TO OPPOSE	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 17170-006001	Application No. 10/077,596
	closure Statement control	Alan D. Snow et al.	
	neets if necessary)	Filing Date February 15, 2002	Group Art Unit 1617
(37 CFR 91.90(0))	- \c_2 - \cdot \cd		

X+= A	n English langua	age abstract provided.**=Already provided
.5	AW	Benson et al. "Serum Amyloid a Protein in Amyloidosis, Rheumatic, and Neoplastic Diseases," Arthritis and Rheumatism, 22(1): 36-42, (1979)
••	AX	Braquet et al. "Ethnopharmacology and the Development of Natural PAF Antagonists as Therapeutic Agents," Journal of Ethnopharmacology, 32:135-139, (1991)
	AY	Calis et al, "Flavonoid, Iridoid, and Lignan Glycosides from <i>Putoria calabrica</i> ," J. Nat. Prod. 64:961-964, (2001)
	AZ	Castillo and Templeton, "Structure and metabolism of multiple heparan sulphate proteoglycans synthesized by the isolated rat glomerulus", Biochimica et Biophysica Acta, 1136:119-128 (1992)
	ВА	Castillo and Templeton, "Subunit structure of bovine ESF (extracellular-matrix stabilizing factor(s)) A chondroitin sulfate proteoglycan with homology to human Iαi (inter-α-trypsin inhibitors,"", FEBS, 318(3): 292-296 (1993)
**	BB	Castillo et al. "Sulfate content and specific glycosaminoglycan backbone of perlecan are critical of perlecan't enhancement of islet amyloid polypeptide (Amylin) Fibril formation." <i>Diabetes</i> , 47: 612-620, (1998).
	ВС	Castillo et al., "Laminin inhibition of beta-amyloid protein (A beta) fibrillogenesis and identification of an A beta binding site localized to the globular domain repeat on the laminin a chain", J. Neurosci. Res., 62(3):451-462 (2000)
	BD	Castillo et al., "The sulfate moieties of glycosaminoglycans are critical for the enhancement beta- amyloid protein fibril formation", J. Neurochem., 72(4):1681-1687 (1999)
**	ВЕ	Castillo. "Novel Purification and detailed characterization of perlecan isolated from the engelbreth-holm-swarm tumor for use in an animal model of fibrillar AB amyloid persistence in brain." J. Biochem. 120(2):433-444, (1996).
**	BF	Castillo. "Perlecan Binds to the β-amyloid proteins (Aβ) of alzheimer's desiase, Accelerates Aβ fibril formation, and Maintains Aβ fibril Stability, "Journal of Neuochemistry, 69(6): 2452-2465, (1997).
<u>-</u>	BG	Clark et al, "Islet Amyloid, Increased A-Cells, Reduced B-Cells and Exocrine Fibrosis: Quantitative Changes in The Pancreas in Type 2 Diabetes," <i>Diabetes Res.</i> 9:151-159, (1988)
	вн	Conway et al., "Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease," Nature Med. 4:1318-1320, (1998)
**	BI	Cooper et al. "Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients." <i>Proc. Natl. Acad. Sci. USA</i> , 84:8629-8632, (1987)
	ВЈ	Crutcher et al., "Cellular and molecular pathology in Alzheimer's disease", Hippocampus, 3:271-287 (1993)
**	вк	Cutler et al. "Correspondence: Tacrine in Alzheimers Disease," The New England Journal of Medicine, pp. 808-810, (Mar. 18, 1993.)
	BL	Czochanska et al, "Direct Proof of a Homogeneous Polyflavan-3-ol Structure for Polymeric Proanthocyanidins," J.C. S. Chem. Comm. pp. 375-377, (1979)
	ВМ	Derwent Abstract, Accession Number 7950380 citing JP 1151514 published June 14, 1989, "Compsns. For treating and preventing nervous diseases – contains carboxylic acid, pref. gallic or pyrogallol-4-carboxylic acid, esp. useful fro alzheimers disease – contains carboxylic acid, pref. gallic or pyrogallol-4-carboxylic acid, esp. useful for alzheimers disease."
2	BN	Ferreira et al, "Tetrahedron Report Number 308: Diversity of Structure and Function in Oligomeric Flavanoid," Tetrahedron 48:1743-1803, (1992)

Examiner Signature	Say	Date Considered	6/9/04
EXAMINER: Initials citation con next communication to applicant	sidered. Draw line through citation if no	t in conformance and r	not considered. Include copy of this form with
			Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
Information Disci by App	osure Statement Colicant	Applicant Alan D. Snow et al.	
(Use several she	1 TAND 3 11 /UUN 751	Filing Date February 15, 2002	Group Art Unit 1617

X+=	An Eng	lish langua	ge abstract provided **=Already provided
5	M	ВО	Fletcher et al, "Plant Proanthocyanidins. Part 3. Conformational and Configurational Studies of Natural Procyanidins," JCS Perkin 1:1628-1637, (1977)
**		ВР	Flood et al. "Amnestic effects in mice of four synthetic peptides homologous to amyloid B protein from patients wit alzheimer disease." <i>Proc. Natl. Acad. Sci. USA</i> , 88:3363-3366 (1991)
**		BQ	Flood et al. "An amyloid β -protein fragment, A β [12-18], equipotently impairs post-training memory processing when injected into different limbic system structures." <i>Brain Research</i> 663:271-276 (1994).
		BR	Fraser et al., "Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues", J. Mol. Biol., 244(1):64-73 (1994)
		BS	Fukuchi et al., "Increased expression of beta-amyloid protein precursor and microtubule-associated protein tau during the differentiation of murine embryonal carcinoma cells", <i>J. Neurochem.</i> , 58(5):1863-1873 (1992)
**		вт	Games et al. "Alzheimer-type neuopathology in transgenic mice overexpressing V717F B-amyloid precursor protein." <i>Nature</i> , 373: 523-527 (1995)
**		BU	Gejyo et al. "A New Form of Protein Associated with Chronic Hemodialysis was Identified as B2 Metroglobulin," <i>Biochemical and Biophysical Research Communications</i> , 129(3): 701-706, (1985).
**		BV	Gejyo et al. "\(\beta^2\)-Metroglobulin: A New Form of Protein Associated with Chronic Hemodialysis," \(Kidney International, 30:385-590 (1986). \)
**		BW	Glenner et al. "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <i>Biochemical and Biophysical Research Communications</i> , 120(3): 885-890 (1984)
**		BX	Grundke-Iqbal et al. "Abnormal Phosphorylation of the Microtubule-Associated Protein Tau Alzheimer Cytoskeletal Pathology," Proc. Natl. Acad. Sci. USA, 83:4913-4917 (1986)
		BY	Gujer et al, "Glucosylated Flavonoids and Other Phenolic Compounds From Sorghum," Phytochemistry 25:1431-1436 (1986)
**		BZ	Haass et al. "The swedish mutation causes early-onset alzheimer's disease by β-secretase cleavage with in the secretory pathway." <i>Nature Medicine</i> 1(12):1291-1296 (1995).
**		CA	Harada et al. "Human Amyloid Protein: Chemical Variability and Homogeneity," Journal of Histochemistry and Cytochemistry, 19(1): 1-15 (1970)
		СВ	Hardy et al., "Framing β-amyloid", Nature Genet., 1:233-234 (1992)
**		СС	Harrigan et al. "Beta Amyloid is Neurotoxic in Hippocampal Slice Cultures," The Neurobiology of Aging, 16(5): 779-789, (1995)
		CD	Hart et al., "Overproduction of perlecan core protein in cultured cells and transgenic mice", J. Pathol., 194(2):262-269 (2001)
		CE	Hashimoto et al., "Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease," <i>Brain Res.</i> 799:301-306, (1998)
		CF	Hertel et al., "Inhibition of the electrostatic interaction between β-amyloid peptide and membranes prevents β-amyloid-induced toxicity," <i>Proc. Natl. Acad. Sci. USA</i> 94: 9412-9416 (1997)
		20	Hemingway et al, "Linkage Isomerism in Trimeric and Polymeric 2,3-cis-Procyanidins," J. Chem. Soc. Perkins Trans. 1:1209-1216 (1982)
		СН	Ho et al. "Phytochemicals in Teas and Rosemary and Their Cancer-Preventive Properties," ACS Symp. Ser. (Food Phytochemicals for Cancer Prevention II) vol. 547, pp. 2-19 1994.

Examiner Signature	Sed	Date Considered 6/9/04
EXAMINER: Initials citation connext communication to applican		ot in conformance and not considered. Include copy of this form with
		Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Prademark Stice	Attorney's Docket No. 17170-006001	Application No. 10/077,596
by Ar	closure Statement pplicant	Applicant Alan D. Snow et al.	
(Use several sh	neets if necessary R 3	Filing Date February 15, 2002	Group Art Unit 1617

X+= An English language abstract provided.

**=Already provided

	_		
/		CI	Hsiao et al. "Age-related CNS Disorder and early death in transgenic FVB/N mice overexpressing
7		Ci	alsheimer amyloid precursor proteins." Neuron, vol. 15, 1203-1218, Nov., 1995.
**		C1	Husby et al. "Nomenclature of Amyloid and Amyloidosis," Bulletin of the World Health Organization, 71(1):105-108, (1993)
		CK	Ishimaru et al, :Flavan-2-ol and Procyanidin Glycosides from Quercus Miyagii," Phytochemistry 26:1167-1170, (1987)
**		CL	Jain et al. "Antiinflammatory Effects of an Ayurvedic Preparation, Brahmi Rasayan, in Rodents," Indian Journal of Experimental Biology, 32:633-636 (1994)
**		СМ	Johnson et al. "Islet Amyloid Polypeptide: Mechanisms of Amyloidogenesis in the Pancreatic Islet and Potential Roles in Diabetes Mellitus," <i>Laboratory Investigation</i> , 66(5): 522-534, (1992)
**		CN	Johnson et al. "Islet Amyloid, Islet-Amyloid Polypeptide, and Diabetes Mellitus," The New England Journal of Medicine, 321(8): 513-518, (1989)
		со	Jones et al, "The Condensed Tannins of Pasture Legume Species," <i>Photochemistry</i> , 15:1407-1409 (1976)
		СР	Jucker et al., "Age-related deposition of glia-associated fibrillar material in brains of C57BL/6 mice", Neuroscience, 60(4):875-889 (1994)
**		cQ	Kamei et al. "Amyloidosis Associated with Juvenile Rheumatoid Arthritis," Acta Pathol. Jpn., 32(1):23-33 (1982)
		CR	Kashiwada et al, "Tannins and Related Compounds. XCIII." Occurnce of Enantiomeric Proanthocyanidins in the Leguminosae Plants, Cassia fistula L. and C.javanica L.," Chem. Pharm. Bull. 38:888-893 (1990)
		CS	Kim et al, "Neuroprotective Constituents from Hedyotis diffusa," J. Nat. Prods. 64:75-78, (2001)
**		СТ	Kitaguchi et al. "Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity," <i>Nature</i> , 331:530-532, (1988)
**		CU	Kosik et al. "MicrotubuleAssociated Protein Tau is a Major Antigenic Component of Pairedd Helicule Filaments in Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 83:4044-4048 (1986)
		CV	Krüger et al., "Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease," Nature Genet. 18:106-108, (1998)
		CW	Latimer et al. "71. Inhibitors of Amyloid-β Aggregation: Dimeric Catechols Inhibit Aggregation and Deposition of Aβ," American Chemical Society 221 st National Meeting, San Diego, CA April 1-5, 2001 (MEDI 071) [posted on 03/23/01]
**		СХ	Lee et al. "A68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau," Science, 251: 675-678, (1991)
**		CY	Levine. "Thioflavine T interaction with synthetic alzheimer's disease B-amyloid peptides: Detection of amyloid aggregation in solution." <i>Protein Science</i> , 2:404-410, (1993)
**		CZ	Levine. "Thioflavine T interacton with amyloid B-sheet structures. "Amyloid: Int. J. Exp. Clin. Invest. 2:1-6, (1995)
		ÐA	Lorenzo et al, "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus," Nature 368:756-760, (1994)
"5	X	DB	Mandybur et al. "Cerebral Amyloid Angiopathy: The Vascular Pathology and Complications," Journal of Neuropathology and Experimental Neurology, 45(1): 79-90, (1986).

Examiner Signature	Se	Date Considered 6/9/64
EXAMINER: Initials citation of next communication to applic		it in conformance and not considered. Include copy of this form with
		Substitute Disclosure Form (PTO-1449)

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Pademade Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
	Information Disc by Ap	closure Statement	Applicant Alan D. Snow et al.	
	(Use several sh	pplicant neets if necessary AR 3 0 7004	Filing Date February 15, 2002	Group Art Unit
ı	(37 CFR §1.98(b))	192 ch		

X+= An English anguage abstract provided. TRADE

**=Already provided

			Maresh et al., "Detection and quantitation of perlecan mRNA levels in Alzheimer's disease a normal
1	F(//	DC	aged hippocampus by competitive reverse transcription-polymerase chain reaction", J. Neurochem.,
			67(3):1132-1144 (1996)
1			Masters et al. "Amyloid Plaque Core Protein in Alzheimers Disease and Down Syndrome," Proc.
**		DD	Natl. Acad. Sci. USA 82:4245-4249 (1983)
			Matthews et al, "Method for estimation of Proanthocyanidins based on their acid depolymerization
		DE	in the presence of nucleophiles," J. Agric. Food Chem. 45:1195-1201, (1997)
		DE	Mattice et al, "Molecular weight averages and 13C NMR intensities provide evidence for branching
	1	DF	in proanthocyanidin polymers," Phytochem. 23(6):1309-1311, (1984)
**		- 6	McAdam et al. "Association of Amyloidosis with Erythema Nodosum Leprosum Reactions and
**		DG	Recurrent Neutrophil Leucocytosis in Leprosy," The Lancet, pp. 572-576, Sep. 27, 1975.
**		D.:	Metaxas et al. "Familial Mediterranean Fever and Amyloidosis," Kidney International, 20:676-685,
**		DH	(1981)
			Miller et al., "Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in
1		DI	vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent
	1		hippocampus", Gila, 21(2):228-243 (1997)
		DJ	Morimoto et al, "Tannins and Related Compounds. LXI." Isolation and Structure of Novel Bi- and
		נט	Triflavanoids from the leaves of Cassia fistula L," Chem. Pharma. Bull. 36:39-47, (1988)
**		DK	Murrell et al. "A mutation in the amyloid recursor protein associated with hereditary alzheimer's
''		אט	disease." Science, 254: 97-99 (1991)
		DL	Nahri et al. "Both familial Parkinson's disease mutations accelerate α-Synuclein aggregation," J.
		DL	Biol. Chem. 274:9843-9846 (1999)
		Naiki et al. "Kinetic analysis of amyloid Fibril polymerization in vitro." Laboratory Investigation,	
L	65(1):104-110, (1991)		
**		DN	Naiki, H. and K. Nakakuki, "First-order kinetic model of Alzheimer's β-amyloid fibril extension in
	1	DIV	vitro, "Laboratory investigation, 74(2):374-383 (1996)
1		DO	Niwano et al., "Inhibitory action of amyloid precursor protein against human Hageman factor (factor
			XII)," J. Lab. Clin. Med. 125:251-6 (1995)
	1		Nonaka et al, "Tannins and Related Compound. XV.") A New Class of Dimeric Flavan-3-ol
1		DP	Gallates, Theasinensins A and B, and Proanthocyanidin Gallates from Green Tea Leaf. (1)," Chem.
L	1		Pharm. Bull. 31:3906-3914, (1983)
l			Pardridge et al. "Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial
**		DQ	Sequence of a 4,200-Dalton Peptid Isolated from Cortical Microvessels," Journal of Neurochemisty,
			49(5): 1394-1401, (1987)
		DR	Patent Abstracts of Japan citing Japanese Patent 10-245342 published September 14, 1998, "Agent
			for reducing neural toxicity of beta-amyoloid protein" Pike et al. "In Vitro Aging of β-Amyloid Protein Cause Peptide Aggregation and Neurotoxity,"
**		DS	,
├			Brain Research, 563:311-314, (1991)
**		DI	Pike et al. "Structure-Activity Analyses of β-Amyloid Peptides: Contributions of the β25-35 Region
		/	to Aggregation and Neurotoxicity," Journal of Neurochemistry, 64(1): 253-265, (1995)
1.5	Y	DU	Ponte et al. "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase
	//_	L	Inhibitors," <i>Nature</i> , 311:525-527, (1988)

Examiner Signature		Date Considered / / /
" ' ' ' '	Second	6/9/07/
		1.1104
EXAMINER: Initials citation of	onsidered. Draw line through citation if no	ot in conformance and not considered. Include copy of this form with
next communication to applica		
		Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17170-006001	Application No. 10/077,596
by Ap	closure Statement Cres	Alan D. Snow et al.	
(Use several sh (37 CFR §1.98(b))	1 .0.40 u	Filing Date February 15, 2002	Group Art Unit 1617

X+= An English Janguage abstract provided TRANSLINE

**=Already provided

	/	A THAT
590	DV	Porter et al, "Isolation of three naturally occurring O-β-glucopyranodsides of procyanidin polymers," Phytochemistry 24:567-569, (1985)
	DW	Porter, L.J, "Flavans and proanthocyanidins," Chapter 2 in Flavans and proanthocyanidins Advances in Research since 1986, J B Harborne (Ed.) London: Chapman and Hall pp. 23-55, 1994
	DX	Porter, J.J., "Flavans and proanthocyanidins," Chapter 2 in <i>The FlavanoidsAdvances in Research since 1980</i> , J B Harborne (Ed.), London: Chapman and Hall, pp. 21-62, 1988
	DY	Prieur et al, "Oligomeric and polymeric procyanidins from grape seeds," <i>Phyochem.</i> 36:781-784, 1994
	EA	Rogers et al., "Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study", Eur. Neuropsychopharmacol., 8:67-75 (1998)
	EB	Sang et al, "Iridoid Glycosides from the leaves of Morinda citrifolia,": J. Nat. Prod. 64:799-800 (2001)
	EC	Santos-Buelga, C. and A. Scalbert, "Proanthocyanidins and tannin-like compounds – nature, occurrence, dietry intake and effects on nutrition and health," J. Sci Food Agri. 80: 1094-1117, (2000)
**	ED	Saraiva et al. "Amyloid Fibral Protein in Familial Amyloidotic Polyneurotherapy, Portugese Type," J. Clin. Invest. 74:104-119 (1984)
**	EE	Saraiva et al. "Studies on Plasma Transthyretin (Prealbinum) in Familial Amyloidotic Polyneropathy, Portugese Type," J. Lab. Clin. Med. 102(4): 590-603, (1983)
	EF	Sekiguchi et al., "Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation", J. Neurosci. Res., 38(6):670-686 (1994)
**	EG	Skinner et al. "The Prealbinum Nature of the Amyloid Protein in Familial Amyloid Polyneuropathy (FAP)-Swedish Variety," <i>Biochemical and Biophysical Research Communications</i> , 99(4):1326-1332, (1981)
	ЕН	Snow et al., "An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar Aβ-amyloid in rat brain", <i>Neuron.</i> , 12(1):219-234 (1994)
	EI	Snow et al., "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", <i>Arch. Biochem. Biophys.</i> , 320(1):84-95 (1995)
	EJ	Snow et al., "Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain", Am. J. Pathol., 144(2):337-347 (1994)
	EK	Snow et al., "Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease", Exp. Neurol., 138(2):305-317 (1996)
	EL	Snow et al., "In vitro and in vivo models to unravel the potential roles of Flavans and β/A4 in the pathogenesis of Alzheimer's disease", Hippocampus, 3(Special Issue):257-268 (1993)
	EM	Snow et al., "Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease", J. Histochem Cytochem., 40(1):105-113 (1992)
-54	EN	Snow. "Proteoplycans in the pathogenesis of alzheimer's disease and other amyloidoses." Neurobiology of Aging, 10:481-497, (1989)

Examiner Signature	$Ca\alpha$	Date Considered	
;	3/)		
		ation if not in conformance and not considered. Include copy of this form with	
next communication to ap	plicant.		
		Substitute Disclosure Form (PTO-1449)	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and traffeman Office	Attomey's Docket No. 17170-006001	Application No. 10/077,596	
	slosure statement	Applicant Alan D. Snow et al.		
(Use several sh (37 CFR §1.98(b))	eets if necessary 3 0 7004	Filing Date February 15, 2002	Group Art Unit 1617	

X+= A	An English langu	age abstract provided **=Already provided
2	EO	Spillantini et al., "α-Synuclein in filamentous inclusions in Lewy bodies from Parkinson's disease and dementia with Lewy bodies," <i>Proc. Natl. Acad. Sci. USA</i> . 95:6469-6473 (1998)
	EP	Stappenbeck et al., "80. Inhibitors of Amyloid-\(\beta\) Aggregation: Histidine Residues in A\(\beta\) Play a Crucial Role in Aggregation," American Chemical Society 221st National Meeting, San Diego, CA April 1-5, 2001 (MEDI 080) [posted on 03/23/01]
**	EQ	Steinberg. "Uncaria Tomentosa (cat's Claw) A wondrous herb from the peruvian rain forest." Townsend Letter for Doctors-pp, 442-443, may 1994.
**	ER	Tamaoka et al. "Amyloid B protein 1-42/43(AB 1-42/43) in crebellar diffuse plaques: enzyme- linked immunosorbent assay and immunocytochemical study." <i>Brain Research</i> 67:151-156 (1995)
**	ES	Tamaoka et al. "Biochemical evedence for the long tail form of amyloid B protein as a seed molecule in cerebral deposits of alzheimer's disease." Biochemical and biophysical research communications, 205(1): 834-842, (1994)
**	ET	Tanzi et al. "Protein Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease," <i>Nature</i> , 331:528-532, (1988)
**	EU	Tawara et al. "Amyloid Fibril Protein in Type 1 Familial Amyloidotic Polyneurotherapy in Japanese," J. Lab. Clin. Med., 98(6): 811-822, (1981)
	EV	Thompson et al, "Plant Proanthocyanidins. Part 1. Introduction; the Isolation, Structure, and Distribution in Nature of Plant Procyanidins," J. Chem. Soc. Perkins Trans. 1: 1387-1399 (1972)
	EW	Tückmantel, "Studies in Polyphenol Chemistry and Bioactivity. 1. Preparation of Building Blocks from (+)-Catechin. Procyanidin Formation. Synthesis of the Cancer Cell Growth Inhibitor, 3-O-Galloyl-(2R,3R)-epicatechin-4β,8-[3-O-Galloyl-(2R,3R)-epicatechin]," J. Am. Chem. Soc. 121:12073-12081 (1999)
**	EX	Van Broeckhoven et al. "Amyloid β Protein precursor gene and Hereditary cerebral hemorrage with amyloidosis (Dutch)." Science, 248:1120-1122 (1990)
**	EY	Wirth et al. "Pharmacologically active procyanidines from the bark of Uncaria tomentosa." Phytomedicine, vol. 4 (3), pp. 265-266, 1997.
	EZ	Wood et al., "α-synuclein fibrillogenesis is nucleation-dependent," J. Biol. Chem. 274:19509-19512, (1999)
	FA	Zhang et al, "Potentillanin, A Biflavanoid and a procyanidin glycoside from potentilla viscosa," Phytochemistry 27:3277-3280, (1988)
	FB	English Language Translation of Japanese Patent 10-245342.
5/3	FC	Hashimoto et al, "Tannins and related Compounds. XC. 8-C-Ascorbyl (-) -Epigallocatechin 3-)- Gallate and novel dimeric Flavan-3-ols, Oolonghomobisflavans A and B from Oolong tea.", Chem

Examiner Signature

Date Considered

Date Considered

EXAMINER: Initials ordation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)